Zhu Cheng-chu, Chen Bao-fu, Kong Min, Wang Chun-guo, Wang Zheng, Ma De-hua, Ye Min-hua, Ye Zhong-rui
Department of Thoracic Surgery, Taizhou Hospital, Zhejiang Taizhou, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Sep;15(9):943-6.
To investigate the feasibility and efficacy of neoadjuvant chemoradiotherapy followed by combined thoracoscopic and laparoscopic esophagectomy (CTLE) in the treatment of advanced esophageal carcinoma.
From June 2011 to February 2012, 11 patients with locally advanced esophageal carcinoma underwent neoadjuvant chemoradiotherapy followed by CTLE (clinical stage IIB-IIIA). NP (vinorelbine pin and cisplatin) or TP (program paclitaxel-pin and cisplatin) were applied as preoperative chemotherapy. During the same period, conventional fractionated radiotherapy was used with the radiation dose of 40 Gy/20 F. At four to six weeks after CRT, 11 patients received three-incision CTLE.
During chemoradiation, 9 patients developed bone marrow suppression. The interval between completion of chemoradiation and surgery was (49.6±15.4) d. Intraoperative findings revealed local fibrosis in one patient (75 days after chemoradiation) while operative difficulty was not increased in the remaining 10 patients. Compared to 15 patients who received surgery alone, operative time was shorter [(242.3±27.0) min vs.(280.5±27.2) min, P=0.002] and intraoperative blood loss was less [(168.2±95.6) ml vs. (244.5±84.8) ml, P=0.042], the number of removal lymph nodes was similar [(19.5±5.8) vs. (20.5±7.1), P=0.683], postoperative hospital stay was prolonged [(18.9±10.3) d vs. (12.5±4.6) d, P=0.020]. The postoperative complication rate was 36.4% including cervical anastomotic leak with pulmonary infection (n=1), cervical anastomotic fistula and hoarseness (n=1), pulmonary infection with pleural effusion (n=2). Follow up ranged from 1 to 9 months, and no recurrence was found.
The neoadjuvant chemoradiotherapy followed by combined thoracoscopic and laparoscopic esophagectomy in the treatment of locally advanced esophageal carcinoma is safe, feasible, and the short-term outcomes are favorable.
探讨新辅助放化疗后行胸腔镜与腹腔镜联合食管癌切除术(CTLE)治疗晚期食管癌的可行性及疗效。
2011年6月至2012年2月,11例局部晚期食管癌患者接受新辅助放化疗后行CTLE(临床分期IIB-IIIA)。采用NP(长春瑞滨和顺铂)或TP(紫杉醇和顺铂)方案进行术前化疗。同期采用常规分割放疗,放射剂量为40 Gy/20 F。在放化疗后4至6周,11例患者接受三切口CTLE。
放化疗期间,9例患者出现骨髓抑制。放化疗结束至手术的间隔时间为(49.6±15.4)天。术中发现1例患者(放化疗后75天)局部纤维化,其余10例患者手术难度未增加。与15例单纯接受手术的患者相比,手术时间更短[(242.3±27.0)分钟对(280.5±27.2)分钟,P = 0.002],术中出血量更少[(168.2±95.6)毫升对(244.5±84.8)毫升,P = 0.042],清扫淋巴结数量相似[(19.5±5.8)对(20.5±7.1),P = 0.683],术后住院时间延长[(18.9±10.3)天对(12.5±4.6)天,P = 0.020]。术后并发症发生率为36.4%,包括颈部吻合口漏伴肺部感染(n = 1)、颈部吻合口瘘伴声音嘶哑(n = 1)、肺部感染伴胸腔积液(n = 2)。随访1至9个月,未发现复发。
新辅助放化疗后行胸腔镜与腹腔镜联合食管癌切除术治疗局部晚期食管癌安全、可行,短期疗效良好。